跳至主要内容
临床试验/NCT06897605
NCT06897605招募中2 期

Clinical Study Evaluating the Impact of Dapagliflozin on Erythropoiesis-Stimulating Agent Responsiveness in Anemic Patients With Chronic Kidney Disease

Mansoura University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年4月1日最近更新:
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
80
试验地点
1
主要终点
Change in Erythropoiesis stimulating agent therapy dose

研究概览

简要总结

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Dapagliflozin + ESA group

Experimental

patients will receive dapagliflozin 10 mg tablet once daily in addition to standard care therapy of erythropoiesis-stimulating agents (ESA)

干预措施: Dapagliflozin (DAPA) (Drug)

Dapagliflozin + ESA group

Experimental

patients will receive dapagliflozin 10 mg tablet once daily in addition to standard care therapy of erythropoiesis-stimulating agents (ESA)

干预措施: Erythropoiesis Stimulating Agent (Drug)

Control group

Other

patients will receive standard care therapy of erythropoiesis-stimulating agents (ESA)

干预措施: Erythropoiesis Stimulating Agent (Drug)

结局指标

主要结局

Change in Erythropoiesis stimulating agent therapy dose

时间窗: 12 weeks

Difference between two groups in comulative dose of erythropoiesis stimulating agent therapy (E.S.A) in international unit (I.U) at the end of the study.

次要结局

  • Changes in hemoglobin level(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Noha Mansour

Principal investigator-Associate Professor of Clinical Pharmacy-Clinical Pharmacy and Pharmacy Practice Department

Mansoura University

研究点 (1)

Loading locations...

相似试验